Masimo Co. (NASDAQ:MASI) Given Consensus Recommendation of “Moderate Buy” by Analysts

Shares of Masimo Co. (NASDAQ:MASI) have received an average rating of “Moderate Buy” from the seven research firms that are presently covering the firm, MarketBeat reports. Two analysts have rated the stock with a hold rating and five have issued a buy rating on the company. The average 1-year price target among brokers that have covered the stock in the last year is $163.67.

Several analysts recently weighed in on MASI shares. Raymond James upgraded Masimo from a “market perform” rating to an “outperform” rating and set a $170.00 target price for the company in a research note on Wednesday, November 6th. Needham & Company LLC restated a “hold” rating on shares of Masimo in a research note on Wednesday, November 6th. Wells Fargo & Company increased their target price on Masimo from $160.00 to $171.00 and gave the company an “overweight” rating in a research note on Wednesday, November 6th. Piper Sandler increased their target price on Masimo from $165.00 to $180.00 and gave the company an “overweight” rating in a research note on Wednesday, November 6th. Finally, BTIG Research increased their target price on Masimo from $166.00 to $170.00 and gave the company a “buy” rating in a research note on Monday, October 14th.

Masimo Stock Performance

Shares of NASDAQ MASI opened at $161.63 on Tuesday. The company has a debt-to-equity ratio of 0.50, a quick ratio of 1.15 and a current ratio of 2.01. The firm has a market cap of $8.65 billion, a price-to-earnings ratio of 111.47 and a beta of 0.97. The business’s 50-day simple moving average is $133.52 and its 200-day simple moving average is $125.93. Masimo has a 52 week low of $86.94 and a 52 week high of $173.90.

Masimo (NASDAQ:MASI) last issued its quarterly earnings data on Tuesday, November 5th. The medical equipment provider reported $0.98 EPS for the quarter, beating analysts’ consensus estimates of $0.84 by $0.14. The business had revenue of $504.60 million for the quarter, compared to analyst estimates of $502.87 million. Masimo had a return on equity of 14.98% and a net margin of 3.85%. The firm’s revenue for the quarter was up 5.4% on a year-over-year basis. During the same quarter in the prior year, the firm posted $0.63 EPS. As a group, equities research analysts expect that Masimo will post 4.04 earnings per share for the current fiscal year.

Institutional Trading of Masimo

A number of hedge funds have recently modified their holdings of the company. Thrivent Financial for Lutherans lifted its position in shares of Masimo by 42.1% during the 2nd quarter. Thrivent Financial for Lutherans now owns 1,217,357 shares of the medical equipment provider’s stock worth $153,314,000 after buying an additional 360,497 shares during the period. Point72 Asset Management L.P. lifted its position in shares of Masimo by 107.8% during the 2nd quarter. Point72 Asset Management L.P. now owns 677,677 shares of the medical equipment provider’s stock worth $85,347,000 after buying an additional 351,523 shares during the period. Bamco Inc. NY bought a new position in shares of Masimo during the 1st quarter worth approximately $50,781,000. Farallon Capital Management LLC lifted its position in shares of Masimo by 13.6% during the 1st quarter. Farallon Capital Management LLC now owns 1,489,563 shares of the medical equipment provider’s stock worth $218,742,000 after buying an additional 177,914 shares during the period. Finally, Dimensional Fund Advisors LP lifted its position in shares of Masimo by 45.9% during the 2nd quarter. Dimensional Fund Advisors LP now owns 525,594 shares of the medical equipment provider’s stock worth $66,201,000 after buying an additional 165,257 shares during the period. Institutional investors own 85.96% of the company’s stock.

About Masimo

Masimo Corporation develops, manufactures, and markets various patient monitoring technologies, and automation and connectivity solutions worldwide. The company offers masimo signal extraction technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry; Masimo rainbow SET platform, including rainbow SET Pulse CO-Oximetry products that allows noninvasive monitoring of carboxyhemoglobin, methemoglobin, hemoglobin concentration, fractional arterial oxygen saturation, oxygen content, pleth variability index, rainbow pleth variability index, respiration rate from the pleth, and oxygen reserve index, as well as acoustic respiration monitoring, SedLine brain function monitoring, NomoLine capnography and gas monitoring, and regional oximetry.